头孢地嗪对小鼠T细胞亚群的影响

目的研究头孢地嗪对小鼠的免疫调节作用。方法对小鼠分别连续7d注射胸腺肽10mg/kg、头孢地嗪(500mg/kg、200mg/kg、50mg/kg)、头孢曲松500mg/kg及生理盐水后,经流式细胞仪对小鼠T细胞亚群进行检测。结果胸腺肽组、头孢地嗪(500mg/kg、200mg/kg、50mg/kg)组CD4 /CD8 均明显高于头孢曲松组和生理盐水组(P<0.05),而头孢曲松组与生理盐水组无差异(P>0.05)。结论头孢地嗪可通过调整CD4 和CD8 之间的平衡,有效地提高机体的免疫功能。     

Expression profile of altered long non-coding RNAs in patients with HBV-associated hepatocellular carcinoma

In China, hepatitis B virus (HBV) infection is the major cause of hepatocellular carcinoma (HCC), which is called HBV-related HCC (HBV-HCC), but the pathogenesis has not been clearly elucidated. Long non-coding RNAs (lncRNAs) have been paid increasing attention to, as an important regulatory molecule involved in many biological processes, as well as a variety of diseases. This study examined lncRNA that might play an important role in HBV-HCC pathogenesis by conducting lncRNA and mRNA profile comparison between HBV-HCC and normal liver tissues. The differentially expressed lncRNA and mRNA profiles between HBV-HCC and normal liver tissues were analyzed by microarrays. The potential protein-encoding gene regulated by lncRNA, and the biological function (gene ontology, pathway analysis) of the target gene were investigated. The results showed that the expression levels of lncRNA and mRNA in HBV-HCC tissues were different from those in normal liver tissues. As compared with normal liver tissue, 837 (4.30%) lncRNAs exhibited more than two-fold change (P<0.05); 325 were up-regulated, and 512 were down-regulated; 991 (5.70%) mRNAs exhibited more than 2-fold change (P<0.05); 733 were up-regulated and 258 were down-regulated in HBV-HCC tissue. Besides, there were 7 lncRNAs with above 10-fold elevation, 6 lncRNAs with above 10-fold decrease, 18 mRNAs with above 10-fold elevation and 11 mRNAs with above 10-fold decrease. 444 (53.05%) lncRNAs had their corresponding mRNAs, some of which were adjacent to lncRNAs. The biological analysis showed that the target gene of differentially expressed lncRNAs took part in the important bio- logical regulatory function. Target gene-related pathway analysis revealed the pathways in carcinoma and mitogen-activated protein kinase (MAPK) signaling pathways significantly changed in the HBV-HCC tissues as compared with normal liver tissues (P<0.05). It was suggested that as compared with normal liver tissues, the expression of lncRNAs in HBV-HCC tissues changed significantly, and lncRNAs played a key role in the pathogenesis of HBV-HCC probably by mainly regulating the carcinoma-related signaling pathway and MAPK signaling pathways.     

慢性乙型肝炎患者拉米夫定耐药模式及耐药后体内免疫环境的改变

目的探讨慢性乙型肝炎患者发生拉米夫定耐药常见的模式及耐药后体内免疫环境的改变。方法应用PCR及基因测序方法回顾性分析72例发生拉米夫定耐药患者血清HBVDNA多聚酶区基因变异模式,比较72例患者拉米夫定抗病毒6个月时及耐药后血清INF-γ、IL-2、IL-4因子水平与对照组细胞因子的水平差异。结果拉米夫定耐药4种主要的突变模式分别为：单位点rtM204I突变,占34.7%（25/72）;rtL180M＋rtM204V,占30.56%（22/72）;rtL180M＋rtM204I,占16.67%（12/72）;rtV173L＋rtV180M＋rtM204V,占12.5%（9/72）;抗病毒6个月时,未变异组与对照组IL-2（P=0.20）、IFN-γ（P=0.14）、IL-4（P=0.119）水平差异无统计学意义。耐药组HBVDNA发生病毒变异后,IL-2、IFN-γ水平显著低于对照组（P〈0.01）,而IL-4水平则高于对照组（P〈0.01）,差异有统计学意义。结论慢性乙型肝炎应用拉米夫定抗病毒治疗耐药模式主要是rtM204I突变及rtL180M、rtV173L、rtM204V、rtM204I联合变异,发生耐药后慢性乙型肝炎患者体内免疫环境将从Th1优势应答转换为Th2优势应答。     

全程监测加联合用药对乙型肝炎疗效分析

目的探索合理而有效的慢性乙型肝炙长期治疗方案,分析全程督导加联合用药对慢性乙型肝炎治疗效果、方法对在1996年～2002年间二次治疗的678例慢性乙型肝炙患者,进行抗病毒或不进行抗病毒治疗,两次检测患者血清Ⅳ-C和PCⅢ,多因素回归统计学分析结果678例患者进行多因素回归分析表明,抗病毒治疗时间在所有因素中影响最大;其次为监督治疗时间,紧接着是抗纤维化治疗时间,最后分别是非特异性免疫治疗时间和其它治疗方案时间、人为分组后,全程督导治疗加联合治疗的治疗组治疗效果较好,血清学检测指标与其它组相比,有统计学差异、结论在全程监督治疗的情况下,联合抗病毒治疗(干扰素),免疫调节(胸腺肽)和抗纤维化的联合治疗为最佳治疗方案,适宜于慢性乙型肝炎长期抗纤维化治疗。     

右肝区不适或疼痛是肝癌表现的前兆吗

长期在门诊坐诊,经常有很多患者叙述右肝区不适,尤其是那些有乙肝或者丙肝的患者,以为是肝癌的表现,经常紧张得受不了,严重影响生活和工作。而真实情况又如何呢,怎么样正确看待右肝区不适和相关的疾病呢?下面从几个方面来阐述一下肝区疼痛和相关疾病。为什么会形成肝区疼痛肝区疼痛是肝区有炎症等刺激神经系统的一种预警机制。众所周知,肝脏内并没有神经系统,因此肝内血管瘤、囊肿、钙化灶、肝内结节等都不会诱发疼痛的表     

甲胎蛋白升高可怕吗?

正甲胎蛋白(AFP)是一种糖蛋白,正常情况下体内含量较少,不同检测厂家,参考值差异较大。这种蛋白主要来自正在发育肝细胞或肿瘤原始细胞。也可见于孕妇,胎儿出生约两周后AFP从血液中消失。AFP主要在胎儿肝中合成,在胎儿13周后逐渐升高,也是孕妇胎儿肝脏逐渐发育重要标记。在妊娠30周以后维持高峰,出生时血浆中浓度为高峰期的1%左右,在周岁时接近成人水平(低于30μg/L)。AFP在产妇羊水或母体血浆中     

接种流脑多糖菌苗的免疫效果观察

为了解冻干 A 群流脑多糖菌苗的接种反应和免疫效果,我们于1981年11月选择了平昌县部分易感儿童,进行了菌苗接种,并观察了接种反应、免疫前后带菌情况及血清抗体变化,现将结果报告于后。材料和方法一、菌苗:冻干 A 群流脑多糖菌苗系成都生物制品研究所生产。菌苗批号:810824—